MAPT and Alzheimer disease: As predicted, significant differences were observed across neuropsychological test scores (e.g., MoCA‐B and ACE‐III), APOE ε4 positivity rates and AD PET imaging findings (Aβ and tau deposition) as cognitive impairment progressed (all p < 0.001).